Table 2.

Antagonism between BAP1 and PBRM1 in ccRCC.

Study	n	PBRM1	BAP1	BAP1/ PBRM1	Expected double mutants	p value	Odds Ratio (95% CI)
Peña-Llopis et al. (8)	176	89	21	3	13 (9–16)	0.00003	0.10 (0.03 – 0.35)
Guo et al. (17)	98	21	8	0	2 (0–4)	0.20	0.19 (0.01 – 3.43)
Hakimiet al. (29)	185	53	10	1	3 (1–5)	0.18	0.23 (0.03 – 1.83)
TCGA	293	101	22	5	10 (7–13)	0.058	0.37 (0.14 – 1.01)
Total	576	175	40	6	14 (11–18)	0.004	0.29 (0.12 – 0.70)

Number of tumors with specific mutations and expected frequencies. The range of expected double mutants was calculated based on a hypergeometric distribution. Differences between actual and expected values were evaluated with a Fisher’s exact test. The Mantel-Haenszel test was used to integrate odds ratios from the different studies. A fixed 0.5 correction was used to find the odds ratio when there was a frequency of zero. KIRC TCGA data obtained from January, 2013 release. Note that differences in the number of tumors with mutations in PBRM1 with Table 1 reflect how tumors are divided according to SETD2 or BAP1 status. Data from the combination of these studies (the total) are highlighted in bold. Significant P values are also in bold.